A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

Healthy Volunteers Clinical Trial

Official title:

A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04525599
• Other study ID #: 3772-CL-2001
• Secondary ID: 2019-004503-12
• Status: Completed
• Phase: Phase 1
• Start date: September 22, 2020
• Est. completion date: April 6, 2022

Study information

• Verified date: June 2022
• Source: Affinivax, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of three dose levels of ASP3772 in comparison to the active comparator Prevnar 13® (PCV13) in toddlers who have previously been administered the routine three-dose series of PCV13.

This study will also evaluate the immunogenicity (production of an immune response) of three different dose levels of ASP3772 in comparison to the active comparator PCV13 in toddlers who have previously been administered the routine three-dose series of PCV13.

Description:

After screening, participants will be randomized to ASP3772 or PCV13 on Day 1. A single dose of ASP3772 will be administered on Day 1 as an injection into the right or left thigh muscle at one of three dose levels. The participants randomized to PCV13 will receive a single intramuscular injection of the approved dose of PCV13 into the right or left thigh muscle. All participants will remain at the study site for approximately 30 to 60 minutes following vaccination in order for study site personnel to evaluate any immediate reactions, if needed. The participant's parent/legal guardian will observe for reactions, including daily body temperature measurements and tolerability assessments, from Day 2 through Day 7 and record observed events in the electronic diary device.

All participants will have study visits on Day 7 (+ 1 day) and Day 30 (± 5 days) post-vaccination. The Day 7 visit may be conducted on site or by telephone call.The end-of-study visit will occur on Day 180 (± 14 days), which will be a safety follow-up by telephone call.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: April 6, 2022
• Est. primary completion date: April 6, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 12 Months to 15 Months

Eligibility

Inclusion Criteria:

• Subject is a healthy toddler who has previously completed a 3-dose infant series of PCV13 with the last vaccination greater than 2 months prior to study vaccination.

• Subject is afebrile within the last 48 hours (temperature measured orally is < 100 °F [37.8°C]; measured rectally or tympanic is < 101 °F [38.3°C]; measured in an axillary position or temporal is < 98.4 °F [36.9°C]).

• Subject's parent/legal guardian is able to read, understand and complete study questionnaires (i.e., the electronic subject diary device).

• Subject's parent/legal guardian along with the subject is able and is willing to attend all scheduled visits and to comply with the study procedures.

• Subject's parent/legal guardian has access to a telephone.

• Subject's parent/legal guardian agrees not to enroll subject in another interventional study while participating in the present study.

Exclusion Criteria:

• Subject has a known hypersensitivity to any vaccine.

• Subject has an immune disorder(s) (including autoimmune disease) and/or clinical conditions requiring immunosuppressive drugs, known or suspected impairment of immunological function or a history of congenital or acquired immunodeficiency.

• Subject has or his/her mother has known human immunodeficiency virus infection or known to be hepatitis B surface antigen-positive.

• Subject has functional or anatomic asplenia.

• Subject has known neurological or cognitive behavioral disorders including clinically significant developmental disorder and related disorders.

• Subject has any evidence of any unstable or active clinically significant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease.

• Subject has any active malignancy or history of malignancy.

• Subject has been in receipt of intramuscular, oral, intravenous, inhaled or intranasal corticosteroid treatment within 2 weeks prior to study vaccination or is planned to receive these medications within 4 weeks after study vaccination. Note: Use of topical corticosteroids is permitted.

• Subject has received any live-attenuated vaccines within 4 weeks prior to receipt of the study vaccine or inactivated vaccines within 2 weeks prior to receipt of study vaccine.

• Subject has previously received an approved (other than PCV13) or investigational pneumococcal vaccine.

• Subject has had any prior receipt of a blood transfusion or blood products, including immunoglobulins.

• Subject has received investigational therapy within 30 days or 5 half-lives, whichever is longer, prior to screening.

• Subject has received a systemically absorbed antibacterial agent within 7 days prior to study vaccination.

• Subject has a history of microbiologically-proven invasive disease caused by S. pneumoniae.

• Subject has received acetaminophen or nonsteroidal anti-inflammatorydrugs (NSAIDs) within 24 hours prior to receipt of study vaccine.

• Subject has a coagulation disorder.

• Subject's parent/legal guardian is unlikely to adhere to study procedures, keep appointments, or is planning to relocate during the study and the subject cannot be adequately followed for safety according to the protocol.

• Subject who has a condition which makes the subject unsuitable for study participation.

• Subject's parent(s)/legal guardian is an employee of Astellas Pharma Global Development Inc., the study-related contract research organizations (CROs), or the study site.

Related Conditions & MeSH terms

• Healthy Volunteers
• Pneumococcal Disease
• Pneumococcal Infections

Intervention

Biological:
• ASP3772
Intramuscular (IM) injection
• PCV13
Intramuscular injection

Locations

Country	Name	City	State
United States	Emmaus Research Center, Inc	Anaheim	California
United States	Kentucky Pediatric/Adult Research	Bardstown	Kentucky
United States	Meridian Clinical Research	Baton Rouge	Louisiana
United States	Gentle Medicine Associates	Boynton Beach	Florida
United States	Dermatology Trial Associates	Bryant	Arkansas
United States	Coastal Pediatric Associates	Charleston	South Carolina
United States	Pediatrics Medical Associates	East Norriton	Pennsylvania
United States	University of Texas Medical Branch	Galveston	Texas
United States	Houston Clinical Research Associates	Houston	Texas
United States	The Childrens Clinic	Jonesboro	Arkansas
United States	Tanner Clinic	Layton	Utah
United States	Madera Family Medical Group	Madera	California
United States	Pediatric Care	Provo	Utah
United States	MultiCare Institute	Spokane	Washington
United States	PMG Research	Statesville	North Carolina
United States	Oklahoma State University Center for Health Sciences	Tulsa	Oklahoma
United States	Ctr Clin Trials San Gabriel	West Covina	California

Sponsors (1)

Lead Sponsor	Collaborator
Affinivax, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment Emergent Adverse Events (TEAEs)	A TEAE is defined as an adverse event (AE) observed after study vaccination and up to 30 days post-vaccination. A vaccine-related TEAE is defined as any TEAE with a causal relationship assessed as "yes" by the investigator.	Up to Day 30
Primary	Number of Participants With Body Temperature Abnormalities and/or Adverse Events	Number of participants with potentially clinically significant body temperature abnormalities.	Up to Day 30
Primary	Reactogenicity Assessed by Number of Solicited Local Reactions	Local reactions are tenderness, movement restriction, redness/erythema and swelling and induration. Local reactogenicity will be evaluated at approximately 30 to 60 minutes post-dose by study site personnel and recorded in an electronic diary device by the participant's parent/legal guardian while at the study site on day 1. The participant's parent/legal guardian will observe reactogenicity and tolerability from day 2 through day 7, and record observed events daily in the electronic diary device. Grades range from 1 (mild) to 4 (potentially life-threatening).	Up to Day 7
Primary	Reactogenicity assessed by Number of Solicited Systemic Reactions	Systemic reactions are vomiting, diarrhea, fever, irritability, decrease of appetite and increase or decrease in sleep. Body temperature will be assessed pre-dose and approximately 30 to 60 minutes post-dose. The participant's parent/legal guardian will be asked to observe the systemic reactogenicity symptoms from day 2 through day 7 and record observed events daily in the electronic diary device. Grades range from 1 (mild) to 4 (potentially life-threatening).	Up to Day 7
Secondary	Proportion of Participants Achieving a Serotype-specific Anticapsular Polysaccharide Immunoglobulin G (PS IgG) Concentration of = 0.35 µg/mL for ASP3772	PS IgG concentration measure will be used to characterize the immunological response 30 days following administration of ASP3772.	Up to 30 days
Secondary	Proportion of Participants Achieving a Serotype-specific Anticapsular PS IgG Concentration of = 0.35 µg/mL for PCV13	PS IgG concentration measure will be used to characterize the immunological response 30 days following administration of PCV13.	Up to 30 days
Secondary	Proportion of Participants Achieving a Serotype-specific Opsonophagocytic Activity (OPA) Antibody Titer = 1:8 for ASP3772	OPA measure will be used to characterize the immunological response 30 days following administration of ASP3772.	Up to 30 days
Secondary	Proportion of Participants Achieving a Serotype-specific OPA Antibody Titer = 1:8 for PCV13	OPA measure will be used to characterize the immunological response 30 days following administration of PCV13.	Up to 30 days
Secondary	Geometric Mean Titer (GMT) for Serotype-specific OPA for ASP3772	OPA measure will be used to characterize the immunological response 30 days following administration of ASP3772.	Up to 30 days
Secondary	Geometric Mean Titer (GMT) for Serotype-specific OPA for PCV13	OPA measure will be used to characterize the immunological response 30 days following administration of PCV13.	Up to 30 days